Antares Pharma Inc
Antares Pharma Is Expected to Report Positive EPS in 2019
In H1 2018, Antares Pharma (ATRS) reported a loss per share of $0.07, which was higher by $0.02 on a year-over-year (or YoY) basis.
Exploring Antares Pharma’s Current Pipeline of Products
On October 11, 2017, Antares Pharma (ATRS) was notified by the FDA that it had found deficiencies in Xyosted.